ARTICLE
Not all private credit fund liquidity is the same: The market’s evolution and a comparison of Evergreen Fund liquidity terms
May 18, 2026
Read time: 7 min
In recent weeks several well known retail-oriented “evergreen” private credit funds have received redemption requests from their investors, which exceed their share repurchase limits, leading to several concerning newsworthy developments.
These events are one of many areas of attention the $3 trillion private credit market is currently receiving.
Redemption woes being perhaps a “canary” in the private credit fund coal mine, the financial press is focusing on the quality and liquidity of private credit fund assets, bank lending exposure to private credit fund borrowers, collateral quality, the impact of AI on underlying SaaS borrowers, mark downs in the values of some loans, and the anxiety of retail investors, among other things.
Systemic signals?
Are we seeing the early signs of systemic failure in the financial system resembling the Global Financial Crisis (GFC)? Hopefully not. Many of the headlines are about risk management in action and putting the risks in perspective, for example:
- The small percentage of private credit fund loan exposure banks have as compared to all commercial lending by banks.
- The small percentage of retail investors in private credit.
- Numerous private credit funds and other buyers have stepped up to provide financial support to private credit funds that are in the news.
- Fundraising in private credit continues, albeit at a slow and sporadic pace at the moment.
The big lesson from the GFC
In the GFC, private investment funds were not at the center of the systemic failures of poor mortgage loan quality and excess leverage. But hedge funds became a source of liquidity for investors, and many hedge funds experienced extreme requests for liquidity.
Private credit funds, per se, did not yet exist, and private credit (“fixed income”) strategies were found mainly in hedge funds. At the time, hedge funds overwhelmingly promised, after an initial lockup period, 100% liquidity to all investors at any quarter end.
When credit markets froze from late 2008 into 2009, credit hedge funds could not liquidate assets to raise cash and failed to fulfill their investors’ redemption expectations. Instead, credit hedge funds had to suspend or cut back redemptions (known as “putting up a gate”) or move their less liquid investments into side pockets (if they had them) to be resolved over time. Hedge funds with too many problems would go into liquidation.
The big lesson from the GFC for the private fund industry was that an asset to fund liquidity mismatch could be fatal for a fund and possibly the fund manager’s business.
Aligning expectations with liquidity
From this difficult period private credit funds emerged, and they were designed to avoid a mismatch between fund investor liquidity expectations and portfolio liquidity. At first this was addressed by housing only liquid investments in hedge funds, which adopted 25% per investor quarterly redemption limits. (These 25% quarterly investor level restrictions were welcomed by fund managers and investors alike as neither group wanted to experience dramatic changes in a fund’s capital base.) Less liquid assets (like middle market loans) would be housed in closed-end fund structures resembling private equity funds (a/k/a “private equity-lite”), which had a five-to-six-year life and economic terms tailored to the private credit asset class. Side pockets, which investors disliked because their size and use could be unpredictable, were banished from the market (they would wisely resurface for other strategies later in the 2010s).
Evergreen funds
The growth of private credit from $100 billion to $3 trillion in the years after the GFC through today is not just a story of the growth of middle market lending by investment funds. The expansion includes at least a dozen types of credit strategies, reflecting the creativity of financiers and the appetite of investors for differentiated fixed income returns. For example, our clients use Evergreen Funds to offer asset-based finance (ABF), real estate lending, airplane finance, FinTech lending, and of course middle market direct lending.
As I have explained in this insider guide to evergreen funds, credit fund managers have been eager to move away from the constraints, costs, and on and off fundraising of managing serial closed-end funds. At the same time, investors are open-minded for credit funds with liquidity terms that are calibrated to the term and liquidity of the particular opportunities. Hence the shift over the last seven to eight years to Evergreen Fund structures.
But not all Evergreen Funds are the same. The driver is the type of investor targeted. Retail investors require an Interval Fund or Business Development Company, which are regulated under the Investment Company Act of 1940 and subject to certain liquidity provisions. High-net-worth investors can invest in registered funds and also private Evergreen Funds, as can institutional investors. Private Evergreen Funds have more flexibility with respect to liquidity terms.
One key attribute for these Interval Funds and certain Business Development Companies is a recurring liquidity offer of 5% to 25% of fund NAV per quarter. (In practice this has most often been 5%, with some of these funds increasing payouts by up to 2% and using liquid assets to raise cash.)
In contrast, non-retail Evergreen Funds can use the “Slow Pay” Evergreen structure, where redeeming investors are placed in an internal liquidating account and are paid out their share of asset proceeds as assets are repaid, refinanced, or sold.
Evergreen fund types and terms
| Evergreen Fund Type | 1940 Act Registered? | Eligible Investors | Tax Reporting | Current Income Distributions | Investor Liquidity | Comments |
|---|---|---|---|---|---|---|
| Interval Fund | Yes | Retail HNW and Institutional |
1099 | Yes | Quarterly 5% to 25% fund wide cap | Some funds facing substantially higher redemption demand have increased the cap by up to 2%. |
| Non-traded BDC | Yes | Retail HNW and Institutional |
1099 | Yes | Quarterly 5% fund wide cap | (Same as Interval Fund) |
| Hedge Fund | No | HNW and Institutional |
K-1 | Yes | Quarterly 25% per investor limit | Good for a mix of liquid and less liquid credit assets |
| Slow Pay Fund | No | HNW and Institutional |
K-1 | Yes | Each redeeming investor gets an internal liquidating account, and redemptions are paid as assets are liquidated in the ordinary course (when repaid, refinanced, sold). No caps apply. | Good for a high percentage of less liquid assets. Some Slow Pay funds also offer other liquidity options, such as buybacks and clean-up calls, to assure full redemptions in a reasonable timeframe. |
The differences have turned out to be important in recent times of economic stress.
Interval Funds and Non-Traded BDCs facing high redemption demand recently had to take the newsworthy and disappointing step of pro rating redemption payouts because a cap had been reached.
In a hedge fund, investors agree in advance to a quarterly cap on the amount of their investment that they can redeem. In a “slow pay” fund, they agree to receive their share of each asset as it liquidates via repayment, refinancing, or sale naturally over time; there is never a need for a cutback.
Conclusions
Fund structures for private credit are diverse. We will see how much investors in retail products will tolerate delayed redemptions. Meanwhile, private credit will continue to have many options to align a desired investor base with fund liquidity and asset liquidity.
*For more than 20 years McDermott Will & Schulte’s fully integrated private capital team has been at the forefront of developing private credit funds and private evergreen fund structures.
Links to our other Evergreen Fund publications:

New hospice, home health agency providers subject to CMS enrollment moratoria
ARTICLE / CLIENT ALERT
New hospice, home health agency providers subject to CMS enrollment moratoria
May 15, 2026
Read time: 8 min
On May 13, 2026, the Centers for Medicare and Medicaid Services (CMS) announced a six-month nationwide moratoria on new Medicare enrollments for hospice and home health agency (HHA) providers, joining durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) suppliers who were subjected to a nationwide moratorium effective February 27, 2026. CMS has never implemented three nationwide moratoria. The announcement is the latest step in the Trump administration’s “whole-of-government” enforcement approach for service lines that have long been subject to heightened scrutiny because of susceptibility to fraud, waste, and abuse. This coordinated effort between CMS and US Vice President JD Vance’s Anti-Fraud Task Force represents an escalation in CMS’s enforcement efforts related to HHAs, hospices, and DMEPOS suppliers, with far-reaching implications for healthcare transactions, organizational operations, and compliance activities.
CMS’s authority and scope of the moratoria
Under 42 C.F.R. § 424.570(a)(2), CMS may impose a temporary moratorium on newly enrolling Medicare providers and suppliers upon determining significant potential for fraud, waste, and abuse with respect to a particular provider or supplier type, geographic location, or both. CMS previously imposed a more limited geographic moratoria targeting HHAs in Florida, Illinois, Michigan, and Texas between 2013 and 2019. However, the newly implemented moratoria mark the first nationwide enrollment freeze implemented for HHAs and the first time that CMS has exercised its moratorium authority for hospice providers.
In announcing the moratoria, CMS indicated it is carefully scrutinizing the total number of HHA and hospice provider enrollments in geographic locations relative to the total Medicare population and number of practice locations associated with a single location address. CMS observed that potential fraud schemes appear to have migrated across the United States and wrongdoers have easily crossed state lines, including to states that historically have not been a hotbed for HHA or hospice enforcement, thereby justifying a national scope to limit the potential for fraud, waste, and abuse.
Critically, the moratoria apply not only to newly enrolling HHAs and hospice providers, but also to new HHA branch offices and hospice practice locations. HHA branch offices are approved locations or sites from which the HHA provides services within a portion of its total geographic area under the supervision and control of the parent HHA. Hospice practice locations include any physical address from which the hospice is approved to deliver services to Medicare beneficiaries under the same certification number. The moratoria prohibit HHAs or hospices from opening or acquiring net “new” locations, as these sites will be unable to be added to their Medicare enrollment record.
Other than for new locations, the moratoria only affect new enrollment applications. They do not restrict existing providers’ ability to continue participating in Medicare, submit claims for covered services, or make certain changes to their enrollment information. Temporary moratoria do not apply to any of the following:
- Changes in practice location (42 C.F.R. § 424.570(a)(1)(iii) provides that practice location changes are not subject to the moratorium unless the location is changing from a location outside to inside the moratorium area, which is not applicable given the nationwide scope here. It is not clear whether CMS would view a change in practice location (e.g., swapping one location for another) as distinct from adding another practice location to an existing enrollment, which would clearly fall within the moratoria).
- Changes in provider or supplier information, such as phone numbers.
- Changes in ownership (except changes in ownership of HHAs and hospices that would require an initial enrollment because of the 36-month rule).
Notwithstanding, HHAs and hospices must timely and accurately report these updates.
The HHA and hospice moratoria run through November 13, 2026, and may be extended in six-month increments, with any extensions announced in the Federal Register. HHAs and hospices whose enrollment applications were received by the Medicare Administrative Contractor (MAC) prior to May 13, 2026, will be unaffected. CMS has published frequently asked questions (FAQs) that provide further interpretation of the moratoria’s scope.
Implications for HHA and hospice transactions
Since January 1, 2024, CMS has applied the “36-month rule” (42 C.F.R. § 424.550) to both HHAs and hospices. Under this rule, an HHA or hospice that undergoes a change in majority ownership (CIMO) within 36 months after its initial enrollment or most recent CIMO must enroll as a new provider, thus subjecting it to the now-imposed moratorium. A CIMO occurs when an individual or organization acquires more than 50% direct ownership interest via asset sale, stock transfer, merger, or consolidation.
The 36-month rule does not apply to HHAs or hospices in the following instances:
- The HHA or hospice submitted two consecutive years of full cost reports since initial enrollment or the last CIMO, whichever is later. This exception does not apply to low utilization or no utilization cost reports.
- An HHA or hospice’s parent company is undergoing an internal corporate restructuring, such as a merger or consolidation.
- The owners of an existing HHA or hospice change the HHA or hospice’s existing business structure (e.g., from a corporation to a partnership, from an LLC to a corporation, or from a partnership to an LLC) and the owners remain the same.
- An individual owner of an HHA or hospice dies.
Imposition of the moratoria introduces mergers and acquisitions (M&A) complexities and will require additional care when structuring transactions. Under current Medicare rules, the buyer in an asset sale may choose to assume, or accept assignment of, an HHA or hospice’s existing provider agreement and billing number rather than enrolling as a new provider. Absent further CMS guidance, such transactions remain permissible during the moratoria so long as the 36-month rule is not implicated. This transaction structure presumes that the buyer is willing to assume any historical Medicare liability of the seller. An asset transaction without assumption of historical Medicare liability will result in the creation of a new HHA or hospice entity that will not be eligible for Medicare enrollment during the moratorium.
Direct stock or equity purchases do not trigger a new provider enrollment so long as the 36- month rule is not implicated. Structuring transactions at an indirect level (i.e., a transfer at the grandparent level or higher) avoids application of the 36-month rule entirely, which in turn avoids the moratoria. This structure also presumes the buyer is willing to assume any historical Medicare liability of the seller.
Medicaid, CHIP, and state moratoria
CMS’s HHA and hospice moratoria currently only apply to Medicare enrollments. CMS determined that it is currently in the best interests of Medicaid and Children’s Health Insurance Program (CHIP) beneficiaries to allow each state to determine whether to impose HHA and/or hospice moratoria and the scope of any such moratoria. CMS has offered to consult with any states that may wish to implement moratoria in their jurisdictions. While it remains to be seen whether any states (e.g., Florida in the DMEPOS context) will implement such moratoria, there is increasing pressure on states to prevent fraud and abuse from occurring in such programs.
Broader enforcement climate for HHA and hospice providers
California has been a focus for state-led crackdowns and federal congressional investigations into alleged post-acute care fraud. CMS noted in its moratorium announcement that Los Angeles County currently has approximately 12% to 15% of all HHA enrollments nationwide, despite being the place of residence of approximately 3% of the US’s Medicare beneficiaries. Furthermore, in April 2026, the federal Anti-Fraud Task Force suspended 447 hospices and 23 HHAs in Los Angeles alleged to have been responsible for more than $600 million in suspected fraud. While California has maintained its own moratorium on new hospice licenses since January 1, 2022, the state’s Department of Public Health has revoked approximately 280 hospice licenses and announced that it is actively reviewing another 300 providers.
CMS also stated in its moratoria announcement that it will use advanced data analytics to intensify its targeted investigations of HHAs and hospices and accelerate their removal (i.e., deactivate or revoke their enrollment) from Medicare if the provider is suspected of committing fraud.
Key takeaways
Given the increasingly aggressive efforts to combat fraud, waste, and abuse for HHA and hospice providers at both the federal and state levels, stakeholders operating in this environment should focus their compliance efforts and actively monitor evolving developments. This includes:
- Track CMS’s implementation of the moratoria. Watch for moratorium extension notices and any counterpart state Medicaid moratoria. Monitor the FAQs for updates and guidance on additional topics, such as relocation of an HHA branch office or hospice practice location.
- Maintain compliance. Ensure timely enrollment updates, maintain organized documentation, prepare for site visits, and conduct internal auditing. CMS is closely scrutinizing HHA and hospice activity during the moratoria.
- Evaluate M&A structures. Analyze ownership history for CIMO trigger risks. Consider transaction structures that avoid the 36-month rule and new enrollment requirement and ensure appropriate purchase agreement protection and due diligence review.
- Prepare for enforcement. Engage counsel promptly upon receiving inquiries from any federal or state healthcare regulator or any MAC.
Please contact the authors or your regular McDermott Will & Schulte lawyer with any questions.

Pilot models at scale: What George v. Commissioner teaches about the research credit
ARTICLE
Pilot models at scale: What George v. Commissioner teaches about the research credit
May 15, 2026
Read time: 4 min
The US Tax Court’s recent decision in George v. Commissioner, T.C. Memo. 2026-10, addressed the application of the Section 41 research credit to supply qualified research expenses (QREs), focusing on whether chickens used in drug trials can qualify as “supplies.” The case provides useful insight into how courts evaluate technical uncertainty under Section 174 for purposes of the Section 41(d)(1)(A) subtest to qualified research, as well as the process of experimentation requirement under Section 41(d)(1)(C) in determining QREs.
Background
George’s of Missouri, Inc., the taxpayer’s S corporation, raises chickens from hatch to processing and handled the live production side of a large poultry operation. In commercial poultry production, “breeders” are hens that produce eggs while “broilers” are chickens raised for processing and sale. Once hatched, broilers are placed on farms and raised under tightly managed conditions, with producers managing feed composition, vaccines, and medications. To keep flocks healthy and profitable, George’s routinely tested different combinations of drugs, vaccines, feed additives, and the chickens themselves, often across entire flocks in real-world conditions, to evaluate their effectiveness. The dispute in George centered on whether these large-scale, production-level trials to develop a healthier, more uniform chicken qualified the chickens as supply QREs.
The Tax Court’s analysis
The Court examined whether the taxpayer faced the requisite uncertainty with respect to the development of a business component (here, a healthier chicken). In George, vendor testing occurred in controlled, “sterile” environments designed to eliminate external variables, whereas the taxpayer’s operations involved fluctuating temperatures, differing farm conditions, and complex biological interactions that could materially affect outcomes. The Court recognized that successful results in one real-world setting do not necessarily translate to another setting with different production environments, inputs, or biological conditions. As a result, prior success (whether in the lab or in other operational contexts) does not thereby eliminate taxpayer-specific uncertainty as to that setting. Thus, the Court found that taxpayer-specific uncertainty depends on whether the taxpayer faces uncertainty regarding performance under the specific operating conditions at issue.
The Court also addressed the type of trials performed by the taxpayer. The taxpayer did not run controlled lab tests; it raised broilers to full weight under actual production conditions to determine whether treatments worked. The Court found that this real-world testing could satisfy the technical uncertainty standard under Section 174. While additional requirements must be met for property to qualify as a “supply” for research credit purposes, satisfying the Section 174 standard allowed the taxpayer to treat the chickens as pilot models – and thus the chickens themselves, along with feed and other associated costs – as eligible inputs in the QRE analysis. That finding supports the notion that large-scale, production-level testing can qualify as experimentation under Section 174, even where it occurs outside a controlled laboratory setting.
In addition to addressing the Section 174 uncertainty standard, the Court rejected the Internal Revenue Services’ attempt to impose rigid substantiation requirements for the “substantially all” standard under the process of experimentation requirement. The taxpayer did not maintain detailed logs but prevailed by presenting credible testimony and records establishing a process of experimentation. However, the Court made clear that a taxpayer can satisfy the substantially all standard “without the mathematical precision that contemporaneous time logs would provide.” This is a particularly welcome development considering recent audit experiences, where exam teams have increasingly pushed for highly detailed contemporaneous documentation to satisfy the standard.
Key takeaway
Although we do not address all aspects of the Court’s decision, including its analysis of base-period substantiation and penalty protection, its treatment of the uncertainty and process of experimentation standards offers particularly useful guidance for taxpayers evaluating and supporting their QRE claims.
April 2026 alcohol industry update: Home distilling heads for a showdown as states loosen alcohol rules
ARTICLE / CLIENT ALERT
April 2026 alcohol industry update: Home distilling heads for a showdown as states loosen alcohol rules
May 15, 2026
Read time: 4 min
April 2026 brought significant legal and regulatory developments for the alcoholic beverage industry, including a landmark US Court of Appeals for the Fifth Circuit decision striking down the federal home distilling ban and notable state-level changes affecting taxation, trade practices, and sales operations.
Federal flashpoint: Circuit courts split on home distilling ban
Two federal circuit courts recently issued conflicting rulings on the constitutionality of the federal home distilling ban, creating a circuit split that may lead to Supreme Court review.
On April 10, 2026, the Fifth Circuit held unconstitutional the federal prohibition on home distilling in 26 U.S.C. §§ 5178(a)(1)(B) and 5601(a)(6), ruling that the ban violates the Taxation and Necessary and Proper clauses because it operates as an “anti-revenue provision” that prevents distilled spirits from coming into existence, rather than raising revenue, and is not “plainly adapted” to Congress’s taxing power.
Meanwhile, on April 21, 2026, the Sixth Circuit reached the opposite conclusion, upholding the same statutory provisions as constitutional and holding that the ban is a necessary and proper means of collecting the federal excise tax on distilled spirits because home stills are easier to hide and harder to search than bonded premises. The Sixth Circuit also held that the ban shifts consumption from untaxed spirits to taxed spirits, thereby increasing revenue.
The Fifth Circuit decision removes the federal criminal prohibition in Texas, Louisiana, and Mississippi but does not affirmatively legalize home distilling, leaving it in a regulatory gray area subject to state law restrictions and unresolved federal permitting and tax requirements. However, the ban remains in effect in the Sixth Circuit and other circuits that have not yet ruled on the issue.
State developments: Maryland eases trade rules while Kansas expands sales hours
Recent state regulatory developments have introduced significant changes to alcoholic beverage taxation, trade practices, and sales regulations across multiple jurisdictions.
Maryland has updated its trade practices by removing restrictions on variety pack sales, eliminating the pre-approval requirement for brand promotional items costing less than $600 and increasing the maximum bar spend by brand owners, suppliers, and wholesalers at promotional events to $200, including reasonable tips to staff. These updates provide welcome flexibility for promotional activities and variety pack distribution, reducing compliance burdens and administrative costs while enabling more creative marketing strategies and streamlining promotional planning and execution.
Kansas enacted legislation expanding alcohol sales hours to 23 consecutive hours per day (6:00 am through 5:00 am the following day) exclusively during the 2026 FIFA World Cup tournament from June 11 through July 19, 2026. This temporary expansion creates a limited but significant opportunity for increased sales during a major international event. Retailers and suppliers should prepare inventory and staffing strategies to capitalize on the extended hours while ensuring compliance with the authorization’s timeframe and conditions. Companies should also monitor whether this temporary expansion influences longer-term legislative discussions about modernizing alcohol sales hours in Kansas.

Trending in Telehealth: April 2026
ARTICLE
Trending in Telehealth: April 2026
May 14, 2026
Read time: 5 min
Trending in Telehealth highlights monthly state legislative and regulatory developments that impact the healthcare providers, telehealth and digital health companies, pharmacists, and technology companies that deliver and facilitate the delivery of virtual care.
Trending in April:
- Telehealth reimbursement
- Cross-state telehealth practice and continuity of care
- Telehealth practice standards and supervision requirements
- Expansion of telehealth across provider types and care settings
A CLOSER LOOK
Proposed legislation and rulemaking:
- In New York, S 354 passed one chamber and would amend the state public health law to expand reimbursement for telehealth services. The bill would require that healthcare services delivered via telehealth be reimbursed on the same basis, at the same rate, and to the same extent as equivalent services provided in person. The bill clarifies that reimbursement would not extend to facility-based costs not incurred in the delivery of telehealth services.
Finalized legislation and rulemaking:
- Tennessee passed HB 2029, which enacts the Dietetics and Nutrition Practice Act. The legislation defines “telehealth” and authorizes licensed dietitians and nutritionists to provide medical nutrition therapy and other nutrition care services via real-time audio, video, or other media. It also permits certain out-of-state practitioners to provide telehealth services under specified conditions, including for continuity of care.
- Oregon enacted HB 4070, which expands Medicaid telemedicine reimbursement by broadening the categories of eligible providers, including licensed and certain unlicensed providers, community mental health programs, hospitals, and federally qualified health centers.
- Oregon enacted HB 4107, which establishes requirements for urgent care centers, including disclosure of whether telemedicine services are offered. When a provider is unavailable due to illness, emergency, or similar circumstance, an urgent care center may operate temporarily without a licensed healthcare provider onsite if a licensed provider is available via telemedicine and the patient is notified at the first point of contact that services will be delivered through telemedicine.
- Kansas enacted HB 2761, which expressly authorizes the use of telepractice in the delivery and supervision of speech-language pathology services. The law defines “telepractice” as the use of telecommunication and internet-based technology to provide remote intervention services and permits speech-language pathology assistants to deliver teletherapy under the direction of a licensed speech-language pathologist. It also allows supervising speech-language pathologists to satisfy direct supervision requirements via real-time audiovisual technology, provided they can observe and communicate with the assistant during service delivery.
- Kentucky enacted HB 424, which updates the regulation of social work practice and authorizes the provision of services via telehealth. It also establishes requirements for telehealth practice, including informed consent, confidentiality, accessibility, standards of care, documentation, and cross-jurisdiction practice.
- Maryland enacted HB 1483, which repeals the state board’s authority to issue temporary telehealth licenses for clinical professional counselors and social workers, and establishes a limited telehealth exception for continuity of care. Under the exception, certain out-of-state licensed clinical professional counselors may continue providing telehealth services to existing clients for up to six months following the client’s relocation.
- Vermont enacted H 84, which amends the state’s telemedicine and audio-only telephone consultation statutes to prohibit the recording of telehealth or telephone appointments without the consent of both the patient and the provider.
- The Wyoming Board of Medicine adopted an emergency rule amending physician licensure regulations to clarify when out‑of‑state physicians may provide services via telemedicine without obtaining a Wyoming license. The rule specifies that establishing a physician‑patient relationship through telemedicine constitutes “practicing medicine” in the state unless the physician qualifies for an applicable exemption, including limited‑duration consultations with a Wyoming‑licensed attending physician or continuity‑of‑care telehealth services provided to established Wyoming patients for up to six months.
Compact activity:
- In Alaska, HB 110 would enter the state into the Social Work Licensure Compact, facilitating multistate practice, including the provision of services via telehealth.
- In Alaska, HB 173 would enter the state into the Occupational Therapy Compact, allowing licensed occupational therapists to practice across participating states.
- In Iowa, SF 2139 would enter the state into the Athletic Trainer Compact, enabling licensed athletic trainers to provide services across state lines in participating jurisdictions.
- In Ohio, SB 320 would enter the state into the Athletic Trainer Compact.
- In Oklahoma, SB 1653 would enter the state into the Occupational Therapy Compact.
Why it matters:
- States continue to expand reimbursement for telehealth services. Legislative activity reflects a focus on payment parity and broader Medicaid coverage, including reimbursement for services delivered by a wider range of providers.
- Cross-state practice frameworks are evolving. States are refining licensure requirements and adopting continuity-of-care exceptions that allow out-of-state providers to deliver telehealth services under defined circumstances.
- Telehealth is being integrated into more care settings and professions. New laws extend telehealth authority to additional provider types and settings, including dietitians, speech-language pathology assistants, and urgent care centers, while establishing clearer supervision and practice standards.
Telehealth is an important development in care delivery, but the regulatory patchwork is complicated. The McDermott Will & Schulte digital health team works alongside the industry’s leading providers, payors, and technology innovators to help them enter new markets, break down barriers to delivering accessible care, and mitigate enforcement risk through proactive compliance.

IRS roundup: May 1 – May 11, 2026
ARTICLE
IRS roundup: May 1 – May 11, 2026
May 13, 2026
Read time: 3 min
Check out our summary of significant Internal Revenue Service (IRS) guidance and relevant tax matters for May 1, 2026 – May 11, 2026.
May 1, 2026: The IRS Office of Chief Counsel issued Chief Counsel Advice 202618011, addressing whether a taxpayer can apply a revised cost allocation method under Treasury Regulation § 1.482-9 as a set-off in a transfer pricing context. The guidance concludes that a taxpayer may use a revised allocation key if it is more reliable in tracing costs to the benefits received by controlled affiliates, even if the original method was reasonable.
The Office of Chief Counsel explained that a more granular, two-step allocation method linking costs to specific business divisions before apportioning among entities better reflects arm’s-length pricing than a broad allocation based solely on overall revenue. Accordingly, the IRS accepted the taxpayer’s revised method as a valid set-off under § 1.482-1(g)(4), emphasizing that cost allocations must reasonably align with the economic benefits conferred.
May 4, 2026: The IRS issued Revenue Procedure 2026-22, providing indexed employer shared responsibility payment amounts under § 4980H for 2027. The guidance adjusts the statutory amounts to $3,780 under § 4980H(c) and $5,670 under § 4980H(b), reflecting the applicable premium adjustment percentage.
May 5, 2026: The IRS issued Revenue Procedure 2026-21, establishing a significant issue ruling program under the jurisdiction of the Associate Chief Counsel (Corporate) that allows taxpayers to request letter rulings on discrete legal issues within larger corporate transactions rather than requiring rulings on the entire transaction. The program applies primarily to transactions under §§ 332, 351, 355, 368, and 1036 and is intended to improve efficiency and timeliness of rulings by focusing on issues that are germane, specific, and not clearly resolved under existing authority.
The IRS also released its weekly list of written determinations (e.g., Private Letter Rulings, Technical Advice Memorandums, and Chief Counsel Advice)
Recent court decision
May 4, 2026: In Kadau v. Commissioner, T.C. Memo. 2026-37, the US Tax Court held that a taxpayer’s micro-captive insurance arrangement lacked economic substance under § 7701(o) and sustained 40% accuracy-related penalties under § 6662(i) for nondisclosed noneconomic substance transactions, totaling approximately $174,500 for tax years 2012 to 2015. The Court found that the arrangement failed both prongs of the economic substance test, concluding it did not meaningfully change the taxpayer’s economic position and lacked a substantial non-tax business purpose, finding that the taxpayer engaged in a circular flow of funds and paid excessive, non-arm’s-length premiums.
The court further held that the taxpayer failed to adequately disclose the arrangement, justifying application of the heightened 40% penalty rate.

Accelerating access, raising the bar: Key FDA developments over the past six months
ARTICLE / CLIENT ALERT
Accelerating access, raising the bar: Key FDA developments over the past six months
May 11, 2026
Read time: 6 min
Over the past six months, the US Food and Drug Administration (FDA) has pursued a dual regulatory agenda: expanding flexibility to accelerate development and access while sharpening expectations around evidence generation, quality systems, and post‑market accountability. Recent guidance, pilot programs, and enforcement signals reflect an agency willing to adapt its frameworks, but also one that is increasingly focused on how sponsors generate, validate, and sustain evidence across the product life cycle. Below, we highlight key FDA developments from the past six months and their implications for the industry.
Accelerated access, with increased focus on evidence planning
In April 2026, the FDA and the Centers for Medicare & Medicaid Services (CMS) announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, a new initiative intended to expedite Medicare access for certain FDA designated Class II and Class III breakthrough devices. RAPID formalizes early and coordinated engagement between FDA, CMS, and device manufacturers so that evidence generated for FDA pre-market review can also support Medicare coverage determinations. By aligning regulatory and coverage expectations earlier in the development life cycle, particularly around clinical outcomes relevant to Medicare beneficiaries, the pathway is designed to reduce delays that have historically occurred between FDA market authorization and national Medicare coverage decisions.
Related FDA pilot programs, including the Technology-Enabled Meaningful Patient Outcomes (TEMPO) program, further reflect the agency’s effort to integrate regulatory oversight and coverage models earlier in the product life cycle. TEMPO introduces a risk‑based enforcement approach for certain digital health devices addressing cardio‑kidney‑metabolic, musculoskeletal, and behavioral health conditions, allowing manufacturers to deploy products under FDA enforcement discretion while collecting real‑world data to inform future regulatory decisions. Together, these initiatives underscore FDA’s focus on earlier coordination and predictability while reinforcing that accelerated access depends on well aligned evidence generation and operational readiness.
Modernizing evidence standards for precision and individualized therapies
In early 2026, the FDA released draft guidance outlining a new “plausible mechanism framework” for certain individualized and precision therapies, particularly those targeting rare and ultra rare diseases where traditional randomized controlled trials may be infeasible. The framework would not create a new approval pathway but would permit sponsors, in limited circumstances, to establish substantial evidence of effectiveness through focused clinical investigations supported by mechanistic data, natural history evidence, and confirmatory findings. While the draft guidance signals increased openness to flexible trial designs and nontraditional endpoints, the FDA emphasized that statutory approval standards remain unchanged and that flexibility at the pre approval stage would be paired with robust post approval obligations, including ongoing monitoring, transparency, and life cycle evidence generation.
This approach is consistent with other FDA actions in Q1 2026 aimed at modernizing evidence development in small or complex patient populations. In January 2026, the agency issued draft guidance endorsing broader use of Bayesian statistical methods and adaptive trial designs, including the use of prior data, external controls, and iterative analyses to support primary inference. Building on that foundation, in Q2, the FDA announced steps to support real time clinical trial models, including the launch of proof of concept trials that transmit safety signals and endpoint data to the agency on a continuous basis.
Renewed emphasis on quality systems and compliance
Manufacturing quality and inspection readiness remain a focal point of FDA activity. In March 2026, the FDA issued updated guidance on Form 483 responses, emphasizing timely engagement by senior management, comprehensive root cause analysis, and durable remediation rather than narrow corrective actions. Around the same time, the FDA launched the PreCheck pilot program, which allows earlier FDA engagement during pharmaceutical facility development and reflects a broader effort to strengthen supply chain resilience and improve predictability around manufacturing readiness.
The FDA also underscored expectations regarding clinical trial transparency. In April 2026, the agency publicly reminded more than 2,200 sponsors and researchers of their obligations to post trial results to ClinicalTrials.gov and indicated that continued noncompliance could prompt enforcement action.
Enforcement signals in high growth therapeutic areas
FDA leadership statements and enforcement announcements over the past six months reflect increased attention to areas experiencing rapid commercialization, particularly glucagon-like peptide-1 (GLP‑1) drugs. The agency has emphasized scrutiny of compounded GLP‑1 products, importation practices, and promotional claims, especially where marketing extends beyond approved labeling or relies on unsupported efficacy assertions.
For example, the FDA issued warning letters to telehealth companies and compounders for promoting compounded GLP‑1 products using marketing claims that suggest FDA approval, guaranteed effectiveness, or equivalence to FDA‑approved drugs.
Regulatory flexibility for artificial intelligence (AI), digital health, and wearables
The FDA continues to update its oversight framework for AI enabled technologies, software as a medical device, and wearable devices. In January 2026, for example, the agency revised guidance on clinical decision support software and non invasive wearable monitoring products to allow a broader set of lower risk technologies to reach market without premarket review, provided they meet defined criteria.
Other notable developments
- Expanded use of incentive based review programs: The FDA continues to rely on priority vouchers and expedited pathways for drugs and devices addressing serious and rare conditions.
- Reduced reliance on animal testing: The agency reported ongoing progress toward accepting alternative preclinical methods where adequately validated.
- Ongoing refinement of genome editing and gene therapy oversight: Through draft guidance and public statements, the FDA continues to refine safety and development expectations in this evolving area.
- Targeted industry communications: The FDA is increasingly relying on focused announcements and letters to highlight emerging safety, quality, and compliance risks rather than just broad rulemaking.

IRS roundup: April 20 – May 1, 2026
ARTICLE
IRS roundup: April 20 – May 1, 2026
May 7, 2026
Read time: 4 min
Check out our summary of significant Internal Revenue Service (IRS) guidance and relevant tax matters for April 20, 2026 – May 1, 2026.
April 23, 2026: The IRS has reportedly begun the process of terminating a lead criminal investigation agent involved in probes of Malta pension structures and Puerto Rico’s Act 60 tax incentives, raising concerns about the continuity of those enforcement efforts. The agent was actively pursuing complex cases involving wealthy taxpayers and multinational structures, and his removal comes amid broader IRS workforce reductions and enforcement resource constraints.
The development has prompted questions from practitioners and policymakers about whether enforcement momentum in these areas will slow, even as the IRS continues to signal that investigations into offshore pension arrangements and Puerto Rico tax planning strategies remain ongoing.
April 24, 2026: The IRS Office of Chief Counsel issued Chief Counsel Advice 202617012, addressing when small corporations may qualify for a more liberal application of reasonable cause relief from penalties under § 6038A for failure to file Form 5472. The guidance explains that corporations with gross receipts of $20 million or less may be eligible if they meet specific criteria, including a lack of knowledge of the filing requirements, limited US presence, and prompt compliance once notified by the IRS.
The Office of Chief Counsel clarified that a “liberal” standard means the IRS should apply greater flexibility in evaluating reasonable cause, but taxpayers must still demonstrate good faith and reasonable cause to the satisfaction of the secretary.
April 29, 2026: The IRS published a notice announcing a public hearing on proposed regulations under § 45Z (the Clean Fuel Production Credit). The hearing has been expanded to run May 27 – 29, 2026, beginning at 9:00 am EDT each day. The proposed regulations address credit eligibility, life cycle emissions rates, and certification and registration requirements for clean fuel producers. Individuals seeking to attend the hearing must request access by May 22, 2026.
The IRS also released its weekly list of written determinations (e.g., Private Letter Rulings, Technical Advice Memorandums, and Chief Counsel Advice)
Recent court decisions
April 21, 2026: In Liberty Global, Inc. v. United States, in a split decision, the US Court of Appeals for the Tenth Circuit held that the codified economic substance doctrine under § 7701(o) applied to a taxpayer’s multistep transaction. The Court found that the taxpayer’s transaction structure generated no meaningful economic change and had no substantial non-tax purpose.
April 22, 2026: In Simmons v. Commissioner, T.C. Memo. 2026-34, the US Tax Court sustained the IRS’s deficiency determinations and accuracy-related penalties under § 6662(a), holding that the taxpayer failed to adequately substantiate several business and rental deductions. The Court found that the taxpayer did not meet the strict substantiation requirements of § 274(d) for automobile expenses and provided no evidence supporting claimed food expenses while also disallowing interest deductions under § 163(a) because the taxpayer failed to show that the expenses arose from the partnership’s own indebtedness rather than personal obligations.
The Court allowed limited, substantiated advertising expenses related to charity events, but disallowed additional amounts because of insufficient documentation and similarly limited rental repair deductions to substantiated amounts while denying utility deductions where tenants were contractually responsible. The Court upheld penalties, concluding that the taxpayer’s inadequate recordkeeping constituted negligence and that she failed to demonstrate reasonable cause or good faith.

A life cycle approach to private equity financing: What sponsors and lenders need to know
ARTICLE
A life cycle approach to private equity financing: What sponsors and lenders need to know
May 6, 2026
Read time: 5 min
Private equity sponsors and lenders are navigating an environment in which disciplined deal structuring and downside preparedness are increasingly interconnected. From deal origination through closing and exit, collaboration between lenders and borrowers can drive smarter decision-making and better position parties to address challenges that may arise throughout the deal life cycle.
Following our second annual Private Equity Finance Forum, we’ve developed five considerations for strong lender relationships, thoughtful finance structuring, and proactive engagement heading into the remainder of 2026 and beyond.
Establish lender relationships early (and have a plan)
Lender relationships are crucial to the success of any financing structure and become even more critical over time. Before entering into a transaction, parties should consider the following:
- The deal life cycle extends beyond closing. Financing terms are not static, and most borrowers will need to re-engage lenders to address evolving business needs. A collaborative, solutions-oriented approach at origination can promote more constructive discussions later.
- Private credit is a relationship-driven market. Lenders often place significant value on repeat business and may offer more flexibility around economics or terms when a strong sponsor relationship exists.
- Early engagement in stressed situations is critical. Companies that approach lenders proactively, including before liquidity becomes constrained, are better positioned to preserve adaptability, maintain available options, and pursue a consensual solution.
- Preparation fosters credibility. Engagement is most effective when paired with a clear plan, including a defined ask, and alignment among key stakeholders and advisors.
Embrace versatility in deal structures and capital solutions
Structuring decisions at origination should account for both current needs and future uncertainty. To ensure that they do:
- Focus on durability, not just optimization. Overleveraging a business can constrain flexibility, particularly in downside scenarios. Financing structures for portfolio companies should reflect existing leverage and realistic cash flow expectations while capital solutions should be determined on a case-by-case basis.
- Ask what could go wrong. Evaluating potential stress points at the outset of a capital structure can help avoid constraints if performance weakens.
- Maintain your flexibility post-closing. A measured approach at closing, combined with the ability to amend terms as performance evolves, can be more effective than over-engineering a structure upfront.
- Don’t forget about broader capital solutions. Private credit markets are increasingly appealing to borrowers because of their ability to adapt terms and offer solutions beyond traditional senior debt, including hybrid capital and other capital solutions, such as:
- Mezzanine facilities
- Preferred equity
- Holdco payment-in-kind facilities
- First-in-last-out structures
- Make sure refinancings are purpose driven. Leverage headroom should not be the sole factor when a refinancing is being considered. Refinancings are often most effective for portfolio companies when they are tied to an objective, such as extending runway to achieve a set goal or taking advantage of more favorable credit terms under improved market conditions.
Take lender considerations into account when underwriting a deal
Both lenders and sponsors are placing increased emphasis on execution capability and downside resilience. Lenders tend to focus on sectors where they have the most experience, which can influence underwriting decisions. Notably:
- Focus on underwriting factors. Core underwriting factors remain consistent, including deal structure and pricing, sector dynamics and investment outlook, and scalability and growth potential.
- Be attentive to execution risks. When it comes to execution risk, the strength of the sponsor and management team – and their ability to deliver on the business plan – is a top consideration.
- Plan and be transparent. Lenders will want clarity on liquidity, free cash flow, covenant cushion, sponsor equity support, and add-on acquisition strategy.
Identify the root cause of stressed and distressed situations
Challenges may arise from excess leverage, operational underperformance, management issues, regulatory disruption, or broader macroeconomic headwinds. When performance declines, early action and accurate diagnosis are critical to preserving value:
- Distinguish between liquidity and operational issues. The best response may range from a targeted capital infusion to broader operational changes, asset sales, or a full restructuring.
- Know that out-of-court solutions are preferred. Lenders and borrowers generally prefer out-of-court solutions to avoid the costs, delays, and uncertainty that surround a Chapter 11 bankruptcy filing.
- Note that these solutions have limits, however. Holdouts, exchange mechanics, and legacy liabilities such as lease, environmental, or mass tort exposure can still make a Chapter 11 filing the more effective tool in extreme situations.
Acknowledge lender priorities in downside scenarios
As situations become more challenging, lender focus tends to shift. When performance deteriorates, lenders typically look for increased transparency, sponsor support, improved visibility, and greater control. Lenders may also seek:
- New money and capital support, such as additional liquidity, enhanced collateral, or other forms of credit support, such as sponsor guarantees or capital-call agreements.
- Enhanced governance, which may include appointing a chief restructuring officer or similar independent fiduciary and obtaining outside financial advisor oversight.
Lenders will also turn their attention to documentary rights, collateral protection, and potential enforcement actions.
Conclusion
Both private equity sponsors and lenders are increasingly required to take a life cycle approach to financing that integrates origination strategy with restructuring preparedness.
Strong lender relationships, flexible capital structures, disciplined underwriting, and early engagement in stressed situations are key to navigating the current landscape. While each situation is different, a proactive and well-informed strategy can expand available options, facilitate constructive stakeholder engagement, and help preserve value across a range of market conditions.

Can annulled arbitral awards still be enforced? Key insights across major jurisdictions
ARTICLE / CLIENT ALERT
Can annulled arbitral awards still be enforced? Key insights across major jurisdictions
May 6, 2026
Read time: 20 min
Does the annulment of an arbitral award by the courts of the arbitration seat necessarily preclude its enforcement?
An examination of Article V(1)(e) of the United Nations Convention on the Recognition and Enforcement of Foreign Arbitral Awards (New York, 10 June 1958) (conventionally known as the New York Convention) suggests that the answer is not necessarily yes. Under the New York Convention, recognition and enforcement of an award may be refused, at the request of the party against whom it is invoked, if “(e) the award has not yet become binding on the parties, or has been set aside or suspended by a competent authority of the country in which, or under the law of which, that award was made.” The permissive wording of the provision leaves room for divergent approaches at the enforcement stage.
This client alert examines how different jurisdictions apply Article V(1)(e) and considers whether, under their respective legal frameworks, an arbitral award may still be enforced where it has been set aside by the courts at the seat of arbitration.
1. France
Following the seminal Norsolor decision of the Cour de cassation in 1984, French courts have adopted a distinctive approach with respect to international arbitral awards that have been set aside at the seat. This approach rests on two principal lines of reasoning.
First, the annulment of an international arbitral award by a foreign court does not constitute an admissible ground for refusing recognition or enforcement under Article 1520 of the French Code of Civil Procedure, which provides an exhaustive list of grounds on which such refusal may be based.
Second, Article VII of the New York Convention provides that the convention shall not “deprive any interested party of any right he may have to avail himself of an arbitral award in the manner and to the extent allowed by the law or the treaties of the country where such award is sought to be relied upon.” This provision allows contracting states to apply domestic rules that are more favorable to the recognition and enforcement of arbitral awards, even where the Convention would permit refusal.
Although still debated, this solution is commonly explained, from a theoretical standpoint, by a conception of international arbitration that is detached from any particular legal system (chiefly, the arbitral seat) and regards arbitral awards as not belonging to the legal order of any particular state (see E. Gaillard, Aspects philosophiques de l’arbitrage international, The Pocket Books of The Hague Academy of International Law, 2008). Accordingly, the validity of an arbitral award may be reviewed solely by reference to the law of the state where recognition or enforcement is sought (see Cass. civ. 1ère, 29 June 2007, n° 05-18.053 Putrabali; and previously, Cass. civ. 1ère, 23 March 1994, n° 92-15.137 Hilmarton). For instance, this means that the award must not violate French international public policy (ordre public international).
In the past 20 years, the Paris Court of Appeal has extended the findings of the Cour de cassation to domestic arbitral awards issued abroad and set aside by the courts of the seat of arbitration, notwithstanding the existence of a bilateral treaty prohibiting their recognition and enforcement, on the ground that such treaty provisions are incompatible with the fundamental principles governing arbitration (see Cour d’appel de Paris, 29 Sept. 2005, n° 2004/07635, spec. § 10).
More recently, the Paris Court of Appeal reaffirmed this position, albeit on a slightly different basis, in a case concerning an award annulled by the Cameroonian courts while exequatur proceedings were pending in France (see Cour d’appel de Paris, 20 mai 2025, n° 22/13345).
This body of case law, which permits the recognition and enforcement in France of international and domestic arbitral awards that have been annulled at the seat, provided the statutory conditions are satisfied, demonstrates that France is one of the most enforcement-friendly jurisdictions.
2. England and Wales
English courts follow a similar, albeit more limited, approach to the French courts, recognizing annulled awards only in limited circumstances, such as where the foreign annulment decision is contrary to English public policy. However, the most significant decisions on this issue were rendered before the Hague Convention of 2 July 2019 on the Recognition and Enforcement of Foreign Judgments in Civil or Commercial Matters entered into force in the United Kingdom on 1 July 2025.
If an international award is set aside by a court in a jurisdiction whose judgments English law requires to be recognized (for example, from a signatory state to the Hague Convention and the arbitration agreement has not been invoked in the annulment proceedings), English courts may be obliged to give effect to that decision and decline to enforce the award. Indeed, the English courts will be more constrained in such circumstances because the public policy exception is narrower than under the New York Convention and foreign judgments must be recognised unless a defense under the Hague Convention applies. But where no applicable enforcement regime governs recognition of the foreign judgment, the English courts retain discretion to enforce the award.
In practice, enforcing an award that has been set aside at the seat requires clearing a high threshold. Two decisions illustrate the English courts’ approach. In Yukos Capital v. Rosneft Oil [2012] EWCA Civ 855, the Court of Appeal enforced awards that had been annulled by the Russian courts, concluding that the annulments were the product of a “partial and dependent judicial system.” By contrast, in Maximov v. OJSC Novolipetsky Metallurgichesky Kombinat [2017] EWHC 1911 (Comm), the High Court refused to enforce a Russian award that had been set aside in Moscow. The court held that enforcement would only be justified where the foreign annulment decision was so “extreme and incorrect” that it could only have been reached as a result of bias or bad faith, emphasizing that this test sets “a high hurdle for the Claimant to surmount.”
3. Italy
Under Italian law, the recognition and enforcement of foreign arbitral awards are governed by Articles 839 and 840 of the Italian Code of Civil Procedure (“ICPC”), which mirror the New York Convention. While Article V(1)(e) of the NY Convention – in its original English version – provides that recognition and enforcement may be refused where the award has been set aside or suspended at the seat, Article 840, para. 3, no. 5) of the ICPC provides that recognition or enforcement of a foreign arbitral award shall be refused where the award has not yet become binding on the parties or has been annulled or suspended by the competent authority of the state in which, or under the law of which, it was issued.
This wording has been interpreted in the sense that any time an award has been set aside or its enforceability suspended at the foreign (non-Italian) seat of arbitration, the Italian court must refuse recognition and enforcement of that award. This approach is confirmed by case law, according to which, under the current Italian legal framework, the annulment of an arbitral award in the country of origin prevents its recognition and enforcement as per Article 840, para 3, no. 5) of the ICPC (see the Court of Appeal of Rome, Judgement No. 958/2013, dated 18 February 2013; Italian Supreme Court, Judgement No. 17712/2015, dated 7 September 2015), including (in case of partial annulment) the parts of the award that were not subject to the annulment. In this respect, the Italian Court of Cassation expressly excluded the possibility of granting recognition – within the framework of Articles 839-840 of the ICPC – to those parts of an award that remain unaffected by a partial set aside by the court of the seat. (See Court of Cassation, Ord. No. 23211/2024, dated 27 August 2024 (the Court did not issue a final ruling, but instead referred the case to a public hearing in light of the complexity and relevance of the issues raised). Final decision not yet available. See also Court of Cassation, Decision No. 17712/2015.) According to the Supreme Court, Article 840 of the ICPC does not distinguish between total and partial set aside and, therefore, once the award has been set aside, the exequatur procedure concerning the arbitral award itself cannot be used to obtain recognition of the remaining operative parts of the award.
Italian legal scholars generally agree that where an award has been set aside, it is no longer capable of producing effects abroad, since one of the essential conditions for recognition is lacking. Thus, both case law and scholars in Italy do not share the solution adopted in France and take a more conservative stance.
A different view has been developed in legal scholarship with reference to the European Convention on International Commercial Arbitration, concluded in Geneva on 21 April 1961 (the Geneva Convention). Article IX of the Geneva Convention provides that the annulment of an arbitral award in one contracting state shall constitute grounds for refusal of recognition and enforcement in another contracting state only if the annulment is based on one or more grounds listed therein (incapacity of the parties, invalidity of the arbitration agreement, violation of the principle of due process, decisions rendered ultra petita, or irregular constitution of the arbitral tribunal or arbitral procedure). On this basis, Italian scholars have argued that – under the Geneva Convention regime – where a foreign arbitral award has been set aside in a Geneva Convention state for reasons not falling within the grounds listed in Article IX, such set aside should not, per se, imply refusal of recognition and enforcement by Italian courts. However, this interpretation has not been tested yet by Italian courts, given the limited application of the Geneva Convention.
4. United States
In the United States, the case law on the enforcement of annulled awards is less uniform. Recent decisions reflect a degree of scepticism toward foreign annulment proceedings but generally rely on principles of international comity.
The first significant US decision addressing this issue is Chromalloy Aeroservices v. Arab Republic of Egypt, where a US court enforced an award made in Egypt that had been set aside by an Egyptian court. The Chromalloy court held that Article V(1) of the New York Convention provides that a state “may” refuse recognition if one of the listed grounds is established, giving discretion to the court. Like the French courts, the district court relied on Article VII of the Convention to apply more favorable domestic law. It turned to the Federal Arbitration Act (FAA) and established US policy favoring arbitration and the enforcement of international awards. After reviewing the Egyptian annulment decision, the court concluded that refusing to enforce the award would contravene US public policy and the parties’ agreement to arbitrate, and therefore recognized the award.
Other US courts have, at times, adopted similar reasoning. In Corporacion Mexicana de Mantenimiento Integral S de RL de CV v. Pemex-Exploracion y Produccion, 832 F.3d 92 (2d Cir. 2016), the US Court of Appeals for the Second Circuit held that district courts may exercise discretion to enforce an annulled award where the annulment decision in the primary jurisdiction is “repugnant to fundamental notions of what is decent and just.” At the same time, echoing the warning of the English courts, the Second Circuit cautioned that this standard is “high, and infrequently met”.
More recently, in the case of Compañía de Inversiones Mercantiles SA v. Grupo Cementos de Chihuahua SAB de CV, 58 F.4th 429 (10th Cir. 2023), the US Court of Appeals for the Tenth Circuit upheld a district court’s refusal to give effect to a Bolivian court’s annulment of an arbitral award. The court applied a two-part test, asking first whether the annulment decision was contrary to US public policy and, second, whether giving effect to it would undermine US public policy. It concluded that “giving effect to the 2020 Bolivian orders would offend US public policy.”
US courts have, however, also refused to enforce annulled awards under the same general framework. In Baker Marine Ltd v. Chevron Ltd, 191 F.3d 194 (2d Cir. 1999), the US Court of Appeals for the Second Circuit acknowledged the Chromalloy rationale but held that the party resisting enforcement of the annulment decision had “shown no adequate reason for refusing to recognize the judgments of the Nigerian court” that annulled the awards. In addition, the district court in TermoRio SA v. Electranta SP, 487 F.3d 928 (D.C. Cir. 2007) declined to enforce an award that had been annulled at the seat, holding that the foreign annulment decision should be respected unless the annulment proceedings were “tainted.”
Therefore, even when an award has been set aside by the competent courts at the seat of arbitration, this does not necessarily preclude its enforcement elsewhere. The prevailing party may still have an interest in pursuing assets in jurisdictions, such as France, England, and Wales, or the United States, where the annulment of an award by foreign courts does not automatically lead to a refusal of its recognition and enforcement.
Rémi Dalmau coauthored this client alert.
